Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
about
Men with Sickle Cell Anemia and Priapism Exhibit Increased Hemolytic Rate, Decreased Red Blood Cell Deformability and Increased Red Blood Cell Aggregate StrengthHydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).Bone marrow transplantation in sickle cell anaemiaInduction of human gamma globin gene expression by histone deacetylase inhibitorsFuture prospects for treatment of hemoglobinopathies.Butyrate increases the efficiency of translation of gamma-globin mRNA.CTD small phosphatase like 2 (CTDSPL2) can increase ε- and γ-globin gene expression in K562 cells and CD34+ cells derived from umbilical cord blood.Identification and characterization of small-molecule inducers of fetal hemoglobin.Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expressionFunction of GATA transcription factors in hydroxyurea-induced HEL cells.Hydroxyurea for sickle cell disease.Optical measurement of biomechanical properties of individual erythrocytes from a sickle cell patient.Searching for the magic bullet against cancer: the butyrate saga.Recombinant erythroid Kruppel-like factor fused to GATA1 up-regulates delta- and gamma-globin expression in erythroid cellsUpdate on the use of hydroxyurea therapy in sickle cell diseasePopulation pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.End stage renal disease in sickle cell disease: future directions.Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea.Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1.Sickle cell disease: old discoveries, new concepts, and future promise.Absolute Reticulocyte Count Acts as a Surrogate for Fetal Hemoglobin in Infants and Children with Sickle Cell Anemia.Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cellsAdeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo.Nitric Oxide-cGMP Signaling Stimulates Erythropoiesis through Multiple Lineage-Specific Transcription Factors: Clinical Implications and a Novel Target for Erythropoiesis.Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive CrisisRegulation of human fetal hemoglobin: new players, new complexities.Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations.Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes ClarosComment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease.Sickle cell disease in Africa: burden and research prioritiesRegulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vectorImprovement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.Novel therapies targeting the endothelium in sickle cell disease.Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.
P2860
Q28551776-523A50E4-BFF0-4BD6-8897-24C80E99099FQ33345042-98EA507A-8719-4E8B-86A2-022445365E4BQ33385020-3257BD6F-F920-4D0B-AE51-BBC1031B569EQ33598588-68BCFA6A-3F04-43A9-8F68-D23941F1723EQ33606876-1F7FC62E-6413-4D00-885D-F7532043F9A7Q33677601-1539B3C5-57A7-4C58-9A02-1DFBF2E69B01Q33713346-7E9AA4A3-D8A2-426C-A2D0-E08677757219Q33849964-474EFE19-9C5A-4ABB-B59C-3648E83450F8Q34047873-0811545B-998B-4D39-9567-6D2791F0C138Q34109105-E41A2461-2CF5-43FF-B7C0-60D3756453FEQ34281892-4B16AA27-43BA-4EDA-82BA-5BCE6C016B3DQ34347194-5B9A4E25-F808-439B-BF62-89F031D53E7FQ34431562-0F92423B-C74B-4534-A7B5-38CF83BF0199Q34707219-1DB9A207-773E-4883-A0C5-2B489B3162B1Q34737460-5ACEF188-0154-46D0-89E7-3DCEAD2C1354Q35053910-3FE40D46-2509-4B1C-AC92-CCA5DC42967CQ35062685-1ECCE3DD-CEFE-49B1-8BF3-82B1C4ED862DQ35098104-3AB3A388-2A28-4FFD-A028-F7019F70D68FQ35153756-F595CF00-50EB-4EF5-A92E-828635033486Q35584228-281B4799-AD4C-4AC1-9F27-B0CC30B29698Q35604335-661A1AFB-2FE8-401E-81FB-D43770AAA1ABQ35656305-96F9C609-8F40-4F85-9893-C237DDCF7E84Q35723452-C9EF1B57-B954-493E-BC23-517CF279E1DEQ35772140-5943D423-2CA2-41EA-B7FF-D3EC0B146BEAQ35843842-F6DBEC58-68E1-47EA-B59E-62E68B3A3D61Q35848449-221E09E9-B34D-4083-87B6-6033410D30F8Q35881204-481F17A8-9E1B-43C4-A8D2-BFCDE670EE14Q35883886-EFF7C1EE-F7A2-44F7-9148-3843EBE665FAQ35996840-D1BB8C4D-EF88-48E2-9A84-D258A9E5A4B0Q36234547-895F67BC-A0A0-41BD-A0B2-73CCF4E5408FQ36333394-CBE02B4A-7D89-4574-BE87-6F4CEA1B9306Q36462461-8CAA574C-4702-4854-BC0A-74BE1DF39244Q36534009-B925C405-0CAB-49DC-8A10-4E398406A2EDQ36591800-1A472BB0-9DCC-418C-91C6-38B1694848C9Q36713158-5AC160C4-430E-40AD-9DC6-9EF623771EBEQ36715984-E5ABD759-D72A-4C7A-92A9-42EDBF4D58D5Q37142195-858D7EBE-4A79-4B8F-A05D-901B4201C920Q37397152-2CBA7F0D-5C63-495F-97DD-FB818096852EQ37930655-2CAC792A-8B29-4DBF-A2FC-3CBFC0E5AB86Q38289589-898000D9-9A10-40D2-A596-7D0F47BA63BA
P2860
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@en
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@nl
type
label
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@en
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@nl
prefLabel
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@en
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@nl
P2093
P1476
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
@en
P2093
Nienhuis AW
Noguchi CT
Rodgers GP
Schechter AN
P304
P356
10.1056/NEJM199004123221504
P407
P577
1990-04-01T00:00:00Z